Nucleocapsid 203 mutations enhance SARS-CoV-2 immune evasion
Lin, X.; Xue, W.; Zhang, Y.; Fu, B.; Trimpert, J.; Xing, N.; Kunec, D.; Tang, W.; Xiao, Y.; Meng, K.; Shi, S.; Wu, H.; Meng, G.; Zhu, Z.
Show abstract
Previous work indicated that the nucleocapsid 203 mutation increase the virulence and transmission of the SARS-CoV-2 Alpha variant. However, Delta later outcompeted Alpha and other lineages, promoting a new wave of infections. Delta also possesses a nucleocapsid 203 mutation, R203M. Large-scale epidemiological analyses suggest a synergistic effect of the 203 mutation and the spike L452R mutation, associated with Delta expansion. Viral competition experiments demonstrate the synergistic effect in fitness and infectivity. More importantly, we found that the combination of R203M and L452R brings in a 3.2-fold decrease in neutralizing titers to the neutralizing serum relative to L452R-only virus. R203M/L452R show an increased fitness after the initiation of global vaccination programmes, possibly associated with the enhanced immune evasion. Another rapidly emerging variant Omicron also bears the 203 mutation. Thus, we proposed that nucleocapsid mutations play an essential role for the rise and predominance of variants in concern.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions 97%
- A non-spike nucleocapsid R204P mutation in SARS-CoV-2 Omicron XEC enhances inflammation and pathogenicity 97%
- Functional and antigenic characterization of SARS-CoV-2 spike fusion peptide by deep mutational scanning 97%
Similar papers in this journal
Similar papers in this journal
- RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera 96%
- Characterization of SARS-CoV-2 intrahost genetic evolution in vaccinated and non-vaccinated patients from the Kenyan population 96%
- Optimizing the live attenuated influenza A vaccine backbone for high-risk patient groups 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.